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Introduction
The prostanoids are a family of biologically active lipids
derived from the 20-carbon essential fatty acids (LCPUFA)
which are involved in all aspects of the immune response
including the resolution of inflammation. ω3-fatty acids,
EPA DPA and DHA are anti-inflammatory, whilst the ω6-
fatty acid, Arachidonic acid (AA) and its metabolites: 13
(S)-HETE, TXB2, PGF2a and 6-k-PGF1a are pro-inflam-
matory. Liquid Chromatography Tandem Mass Spectro-
metry (LC-MSMS) allows analyses of multiple prostanoids
with high accuracy using 3 mm blood spots. This method
has never been used in JIA and may find biomarkers which
can help predict disease activity and treatment response.
Objectives
To measure prostanoid profiles in patients with JIA
using LC-MSMS.
Methods
254 samples from 114 JIA patients and 6 healthy controls
(HC) were collected onto specially prepared filter papers
and analysed using LC-MSMS.
Results
The JIA M:F ratio was 1:1.4, the average age at study
entry (9.4 ± 5.0 y), average disease duration (56.1 ±
46.1 m), with 25% JIA receiving treatment with
NSAID, 11% with Methotrexate (MTX), and 10% with
Biologics. 13(S)HODE and DHA levels were signifi-
cantly different between JIA patient groups (p = 0.05
for both; 13(S)HODE oligo vs poly p = 0.02; DHA
SoJIA vs RF+ Poly p = 0.007). There was a positive
correlation between JADAS and PGB2 (p = 0.046).
There were lower levels of pro-inflammatory prosta-
noids in JIA (Table 1).
Conclusion
In our JIA cohort, we found that PGB2 is correlated
with disease activity and that levels of pro-inflammatory
prostanoids are reduced, particularly in polyarthritis.
This may reflect the degree to which the pro-resolving
prostanoids are activated in patients with relatively long
average disease duration. It is also possible that mea-
surement of a combination of prostanoids will help us
predict changes in disease activity and treatment
response over time more accurately. Longitudinal analy-
sis the relationship between disease activity and prosta-
noid profiles is underway.
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Table 1
Prostanoid/JIA subtype Oligo Extended Oligo Poly RF+ Poly JPSA ERA SoJIA
HODE p = 0.001 p = 0.002 p = 0.01
DPA p = 0.02 p = 0.017 p = 0.01
PGF2a p = 0.001 p = 0.03 p = 0.007 p = 0.04
TBX2 p = 0.009 p = 0.004 p < 0.001 p = 0.007 p = 0.04
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